Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.

× No keyword cloud information.

10 in total

1. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

Authors: Naoto Takahashi; Chiaki Nakaseko; Yukio Kobayashi; Koichi Miyamura; Chiho Ono; Yuichiro Koide; Yosuke Fujii; Kazunori Ohnishi
Journal: Int J Hematol Date: 2017-04-13 Impact factor: 2.490

2. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Authors: Christian Borgo; Luca Cesaro; Valentina Salizzato; Maria Ruzzene; Maria Lina Massimino; Lorenzo A Pinna; Arianna Donella-Deana
Journal: Mol Oncol Date: 2013-08-22 Impact factor: 6.603

3. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Authors: Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi
Journal: Am J Hematol Date: 2011-09 Impact factor: 10.047

4. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1^T315I in Ph+ CML.

Authors: Karoline V Gleixner; Irina Sadovnik; Mathias Schneeweiss; Gregor Eisenwort; Konstantin Byrgazov; Gabriele Stefanzl; Daniela Berger; Harald Herrmann; Emir Hadzijusufovic; Thomas Lion; Peter Valent
Journal: Leuk Res Date: 2018-12-28 Impact factor: 3.156

5. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Authors: Sofia Zanin; Christian Borgo; Cristina Girardi; Sean E O'Brien; Yoshihiko Miyata; Lorenzo A Pinna; Arianna Donella-Deana; Maria Ruzzene
Journal: PLoS One Date: 2012-11-08 Impact factor: 3.240

Review 6. Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors: Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal: Oncotarget Date: 2015-06-30

7. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.

Authors: Valentina Salizzato; Christian Borgo; Luca Cesaro; Lorenzo A Pinna; Arianna Donella-Deana
Journal: Oncotarget Date: 2016-04-05

8. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.

Authors: Tim H Brümmendorf; Jorge E Cortes; Hanna J Khoury; Hagop M Kantarjian; Dong-Wook Kim; Philippe Schafhausen; Maureen G Conlan; Mark Shapiro; Kathleen Turnbull; Eric Leip; Carlo Gambacorti-Passerini; Jeff H Lipton
Journal: Br J Haematol Date: 2015-11-04 Impact factor: 6.998

9. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Authors: Sara Redaelli; Monica Ceccon; Laura Antolini; Roberta Rigolio; Alessandra Pirola; Marco Peronaci; Carlo Gambacorti-Passerini; Luca Mologni
Journal: Oncotarget Date: 2016-11-08

10. In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.

Authors: Ignazia Tusa; Giulia Cheloni; Martina Poteti; Angela Silvano; Alessandro Tubita; Zoe Lombardi; Antonella Gozzini; Roberto Caporale; Barbara Scappini; Persio Dello Sbarba; Elisabetta Rovida
Journal: Target Oncol Date: 2020-10 Impact factor: 4.493

10 in total